Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation

NCT02493361 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT02493361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02493361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase II, Multicenter Study of Enhancing Pembrolizumab Responses in Melanoma Through Intratumoral pIL-12 Electroporation
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Completed
Start date
August 17, 2015
Completion date
March 2, 2020
Enrollment
24 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma